The evolving UK landscape surrounding entheogens is increasingly nuanced, demanding careful exploration. While therapeutic investigation into compounds like psilocybin and copyright continues to advance, and patient opportunity via private clinics is growing, the policy framework remains ambiguous. This presents a distinctive situation for both see